chr17-47253901-G-A
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BA1BP4
This summary comes from the ClinGen Evidence Repository: The c.40G>A; p.Val14Met missense variant has not been reported in the literature to our knowledge. It is present in an African population at an allele frequency of 0.03606. Computational evidence suggests no impact on the gene or gene product with a REVEL score of 0.115. In summary, this variant meets criteria to be classified as benign for GT. GT-specific criteria applied: BA1 and BP4. LINK:https://erepo.genome.network/evrepo/ui/classification/CA8622831/MONDO:0010119/011
Frequency
Consequence
NM_000212.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ITGB3 | NM_000212.3 | c.40G>A | p.Val14Met | missense_variant | 1/15 | ENST00000559488.7 | NP_000203.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ITGB3 | ENST00000559488.7 | c.40G>A | p.Val14Met | missense_variant | 1/15 | 1 | NM_000212.3 | ENSP00000452786 | P1 | |
ITGB3 | ENST00000571680.1 | c.40G>A | p.Val14Met | missense_variant | 1/9 | 1 | ENSP00000461626 | |||
ITGB3 | ENST00000696963.1 | c.40G>A | p.Val14Met | missense_variant | 1/14 | ENSP00000513002 |
Frequencies
GnomAD3 genomes AF: 0.0103 AC: 1561AN: 151838Hom.: 24 Cov.: 32
GnomAD3 exomes AF: 0.000841 AC: 62AN: 73718Hom.: 0 AF XY: 0.000696 AC XY: 30AN XY: 43080
GnomAD4 exome AF: 0.00100 AC: 1247AN: 1242408Hom.: 27 Cov.: 30 AF XY: 0.000881 AC XY: 538AN XY: 610550
GnomAD4 genome AF: 0.0103 AC: 1559AN: 151946Hom.: 24 Cov.: 32 AF XY: 0.00999 AC XY: 742AN XY: 74306
ClinVar
Submissions by phenotype
not provided Benign:3
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Likely benign, criteria provided, single submitter | clinical testing | Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics | Aug 25, 2015 | - - |
Glanzmann thrombasthenia Benign:2
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 12, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. - |
Benign, reviewed by expert panel | curation | ClinGen Platelet Disorders Variant Curation Expert Panel, ClinGen | Jun 04, 2020 | The c.40G>A; p.Val14Met missense variant has not been reported in the literature to our knowledge. It is present in an African population at an allele frequency of 0.03606. Computational evidence suggests no impact on the gene or gene product with a REVEL score of 0.115. In summary, this variant meets criteria to be classified as benign for GT. GT-specific criteria applied: BA1 and BP4. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at